Randomized Phase III Study of Temozolomide Versus Dacarbazine in the Treatment of Patients With Advanced Metastatic Malignant Melanoma
Top Cited Papers
- 1 January 2000
- journal article
- clinical trial
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 18 (1) , 158
- https://doi.org/10.1200/jco.2000.18.1.158
Abstract
PURPOSE: : To compare, in 305 patients with advanced metastatic melanoma, temozolomide and dacarbazine (DTIC) in terms of overall survival, progression-free survival (PFS), objective response, and ...Keywords
This publication has 18 references indexed in Scilit:
- Multicentre CRC phase II trial of temozolomide in recurrent or progressive high-grade gliomaCancer Chemotherapy and Pharmacology, 1997
- Biochemotherapy studies in the treatment of advanced melanomaMelanoma Research, 1997
- The charing cross hospital experience with temozolomide in patients with gliomasEuropean Journal Of Cancer, 1996
- 3-aminobenzamide and/or O6-benzylguanine evaluated as an adjuvant to temozolomide or BCNU treatment in cell lines of variable mismatch repair status and O6-alkylguanine-DNA alkyltransferase activityBritish Journal of Cancer, 1996
- Melanoma: chemotherapyBritish Medical Bulletin, 1995
- Chemosensitivity to triazene compounds and O6-alkylguanine-DNA alkyltransferase levels: Studies with blasts of leukaemic patientsAnnals of Oncology, 1995
- Depletion of O6-alkylguanine-DNA alkyltransferase correlates with potentiation of temozolomide and CCNU toxicity in human tumour cellsBritish Journal of Cancer, 1993
- Temozolomide: A new oral cytotoxic chemotherapeutic agent with promising activity against primary brain tumoursEuropean Journal Of Cancer, 1993
- Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856)British Journal of Cancer, 1992
- Antitumour imidazotetrazines—XVBiochemical Pharmacology, 1987